Morning sickness drug reintroduced to US


The US Food and Drug Administration (FDA) has approved a drug for morning sickness, 30 years after it was originally removed from the market.

Diclegis (doxylamine succinate and pyridoxine hydrochloride), contains the same active ingredients as Benedictin, which was produced by Merrel Dow and withdrawn from the market in 1983 after a string of lawsuits claiming it caused birth defects.

Rather than fight the litigations, Merrel Dow voluntarily withdrew the product. However, Canadian company Duchesnay continued to market the drug in Canada, under the name Diclectin. Large scale studies have shown the drug to be safe for both mothers and foetuses, so Duchesnay has now decided to expand into the US by applying for approval of its long-release version.

The drug has been approved for use by pregnant women whose morning sickness cannot be controlled through dietary means, such as by eating smaller meals of bland food throughout the day.


Related Content

Chemistry World podcast - January 2014

15 January 2014 Podcast | Monthly

news image

This month, we examine the controversy surrounding the Turin shroud and explore the history of crystallography

Business roundup

26 February 2008 Business

news image

Industry news

Most Read

Bubble wrap could send lab costs packing

23 July 2014 Research

news image

Potential bubbles up across wide range of uses as storage and test vessels, especially for poor countries

Coffee cup confusion

20 July 2014 Research

news image

Scientists call for better labelling after research highlights inconsistencies in the chemical composition of a cup of coffee

Most Commented

Bubble wrap could send lab costs packing

23 July 2014 Research

news image

Potential bubbles up across wide range of uses as storage and test vessels, especially for poor countries

Relativity behind mercury's liquidity

21 June 2013 Research

news image

First evidence that relativistic effects are indeed responsible for mercury's low melting point